Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients.

Alshalalfa, Mohammed; Verhaegh, Gerald W; Gibb, Ewan A; Santiago-Jiménez, Maria; Erho, Nicholas; Jordan, Jennifer; Yousefi, Kasra; Lam, Lucia L C; Kolisnik, Tyler; Chelissery, Jijumon; Seiler, Roland; Ross, Ashley E; Karnes, R Jeffrey; Schaeffer, Edward M; Lotan, Tamara T; Den, Robert B; Freedland, Stephen J; Davicioni, Elai; Klein, Eric A and Schalken, Jack A (2017). Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. OncoTarget, 8(31), pp. 50804-50813. Impact Journals LLC 10.18632/oncotarget.15133

[img]
Preview
Text
Seiler,Oncotarget, lowPCA3.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (3MB) | Preview

BACKGROUND Prostate cancer antigen 3 (PCA3) is a prostate cancer diagnostic biomarker that has been clinically validated. The limitations of the diagnostic role of PCA3 in initial biopsy and the prognostic role are not well established. Here, we elucidate the limitations of tissue PCA3 to predict high grade tumors in initial biopsy. RESULTS PCA3 has a bimodal distribution in both biopsy and radical prostatectomy (RP) tissues, where low PCA3 expression was significantly associated with high grade disease (p<0.001). PCA3 had a poor performance of predicting high grade disease in initial biopsy (GS≥8) with 55% sensitivity and high false negative rates; 42% of high Gleason (≥8) samples had low PCA3. In RP, low PCA3 is associated with adverse pathological features, clinical recurrence outcome and greater probability of metastatic progression (p<0.001). MATERIALS AND METHODS A total of 1,694 expression profiles from biopsy and 10,382 from RP patients with high risk tumors were obtained from the Decipher Genomic Resource Information Database (GRIDTM)prostate cancer database. The primary clinical endpoint was distant metastasis-free survival for RP and high Gleason grade for biopsy. Logistic regression analyses and Cox proportional hazards models were used to evaluate the association of PCA3 with clinical variables and risk of metastasis. CONCLUSIONS There is high prevalence of high grade tumors with low PCA3 expression in the biopsy setting. Therefore, urologists should be warned that using PCA3 as stand-alone test may lead to high rate of under-diagnosis of high grade disease in initial biopsy setting.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Seiler, Roland

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1949-2553

Publisher:

Impact Journals LLC

Language:

English

Submitter:

Laetitia Hayoz

Date Deposited:

07 Mar 2018 13:07

Last Modified:

24 Oct 2019 09:34

Publisher DOI:

10.18632/oncotarget.15133

PubMed ID:

28881605

Uncontrolled Keywords:

PCA3 initial biopsy prognosis prostate cancer under-diagnosis

BORIS DOI:

10.7892/boris.108726

URI:

https://boris.unibe.ch/id/eprint/108726

Actions (login required)

Edit item Edit item
Provide Feedback